These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38072400)

  • 21. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.
    Shi M; Zhang Y
    Anticancer Drugs; 2024 Aug; 35(7):644-652. PubMed ID: 38950136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Top advances of the year: Cervical cancer.
    Podwika SE; Duska LR
    Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.
    Feng L; Shi Q; Wang S; Zhao Y; Wu H; Wei L; Hao Q; Cui Z; Wang L; Zhang J; Zhang D; Zhan X; Jiang J
    BMC Cancer; 2024 Oct; 24(1):1267. PubMed ID: 39394089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
    Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
    Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of systemic treatment in recurrent and advanced cervical cancer: a primer for radiologists.
    Marshall C; Rajdev MA; Somarouthu B; Ramaiya NH; Alessandrino F
    Abdom Radiol (NY); 2019 Apr; 44(4):1506-1519. PubMed ID: 30288585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in immunotherapy for cervical cancer.
    Wendel Naumann R; Leath CA
    Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
    Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
    Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
    Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
    Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
    Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical treatment of metastatic or recurrent cancer of the cervix].
    de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
    Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing paradigms in the systemic treatment of advanced cervical cancer.
    Pfaendler KS; Tewari KS
    Am J Obstet Gynecol; 2016 Jan; 214(1):22-30. PubMed ID: 26212178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
    Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer.
    Ju M; Pan B; Huang Y; Zhou Y; Chen J; Xiang H; Xu S; Chen S; Lan C; Li J; Zheng M
    Cancer Med; 2024 Oct; 13(19):e70204. PubMed ID: 39382194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.
    Mackay HJ; Wenzel L; Mileshkin L
    Am Soc Clin Oncol Educ Book; 2015; ():e299-309. PubMed ID: 25993189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Targeted therapy in locally and metastatic recurrent cervical cancers].
    Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
    Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix.
    Miglietta L; Bruzzone M; Ghione G; Pepe A; Marenghi C; Ragni N; Boccardo F
    Tumori; 2002; 88(3):204-8. PubMed ID: 12195758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
    Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.